<DOC>
	<DOC>NCT01196754</DOC>
	<brief_summary>This is a prospective clinical monocentric study in ICU with sedated ventilated patients with sevoflurane during 48 h with the AnaConda® system, establishing pharmacokinetic model of sevoflurane.</brief_summary>
	<brief_title>Pharmacokinetic of Sevoflurane During a 48h Sedation in Intensive Care Unit With AnaConDa®</brief_title>
	<detailed_description>Prospective clinical monocentric study in ICU with sedated ventilated patients with sevoflurane during 48 h with the AnaConda® system, establishing pharmacokinetic model of sévoflurane and its metabolites (hydroxyfluroisopropanol, fluoride)</detailed_description>
	<mesh_term>Sevoflurane</mesh_term>
	<criteria>Adult patients ventilated more than 48 h Stable respiratory and hemodynamic conditions Consent of patients or family Arterial line Acute kidney injury Obesity Sevoflurane anaphylaxia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Sevoflurane</keyword>
	<keyword>Fluorides</keyword>
	<keyword>Sedation</keyword>
	<keyword>Adult patients with a predicted sedation more than 48 h</keyword>
	<keyword>Stable respiratory and hemodynamic conditions for SBT</keyword>
	<keyword>Consent of patients</keyword>
	<keyword>Arterial line</keyword>
</DOC>